Research Topics
| S EmerySummaryAffiliation: University of New South Wales Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Immune reconstitution in HIV infectionS Emery
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2nd Floor, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
Curr Opin Immunol 9:568-72. 1997..These observations have implications for clinical management, therapeutic strategies, and future research...
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART studySean Emery
Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
J Infect Dis 197:1133-44. 2008..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...- Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 diseaseS Emery
National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW 2010, Australia
J Infect Dis 182:428-34. 2000..98 vs. -0.63 log copies/mL; P=.004). Significant improvements in CD4 cell count and plasma HIV RNA in recipients of IL-2 relative to control patients were associated with a nonsignificant trend toward improved clinical outcome... - The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRITSean Emery
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
Control Clin Trials 23:198-220. 2002..This article describes the rationale supporting the trial in addition to reviewing the study design, coordination, and governance... - HIV medicineSean Emery
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010
Med J Aust 176:21. 2002 - Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapyS Emery
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
Hum Vaccin 3:260-7. 2007..The promising antiretrovirological effect supports further study of FC in a larger trial with a broader population of patients with HIV disease... - Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapyH Byakwaga
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
HIV Med 10:143-51. 2009..The aim of the study was to determine the effect of nucleoside reverse transcriptase inhibitors (NRTIs) on CD4 recovery in HIV-1-infected individuals receiving long-term suppressive combination antiretroviral therapy (cART)... - Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2J Amin
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
HIV Clin Trials 4:252-61. 2003..To compare inhibition of HIV replication, improvements in CD4+ T-cell counts, metabolic parameters, and body shape changes after 2 years of assigned therapy in OzCombo patients... - Immunomodulators as adjunctive therapy for HIV-1 infectionS L Pett
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
J Clin Virol 22:289-95. 2001..However, the immunological competency and therefore clinical impact of this expanded CD4(+) T cell pool is yet to be established; this question is the focus of two large clinical end-point studies, ESPRIT and SILCAAT... - A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 studyA Carr
HIV, Immunology and Infectious Disease Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
AIDS 14:1171-80. 2000..The best-tolerated and most potent initial HAART regimen is unknown and was investigated in this study... - Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-upD Carey
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW, Australia
HIV Med 10:163-72. 2009..Poly-l-lactic acid (PLA) injections modestly increase objectively assessed facial thickness but not facial soft tissue volume (FSTV) over 24 weeks. The durability of this response has not been well defined objectively... - Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study GroupA Carr
HIV Medicine Unit, St Vincent s Hospital, Sydney, Australia
J Infect Dis 178:992-9. 1998..HIV RNA levels were unaffected. IL-2 therapy may expand the existing immune repertoire but not immediately reconstitute lost immune function... - Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapyAlan Winston
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia
J Antimicrob Chemother 56:380-7. 2005..The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals... - Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapyA Winston
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
HIV Med 7:105-11. 2006..The aim of this study was to assess changes in renal parameters in individuals receiving TDF- and non-TDF-containing highly active antiretroviral therapy (HAART)... - Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trialAllison Martin
National Centre in HIV Epidemiology and Clinical Research UNSW, 5St Vincent s Centre for Applied Medical Research, Sydney, Australia
Clin Infect Dis 49:1591-601. 2009..Which fixed-dose-combination tablet is more effective and safe is uncertain... - Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension StudyAllison Martin
National Centree in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
AIDS 18:1029-36. 2004..Nevertheless, the lipodystrophy syndrome was still evident, indicating additional strategies need evaluating... - The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individualsAlan Winston
National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
AIDS 19:1393-9. 2005..We undertook an assessment of NIQ and 48-week virological outcome in patients commencing ritonavir-boosted protease inhibitor (PI) regimens... - The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
Clin Infect Dis 44:1475-83. 2007..Ritonavir-boosted double-protease inhibitor (PI)-only regimens are such an option but are prone to pharmacokinetic interactions... - Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjectsS Emery
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
Hum Vaccin 1:232-8. 2005..Although safe, neither vaccine construct appeared to possess detectable T-cell mediated anti-HIV immunogenic properties in HIV infected individuals, as measured by standard T cell assays... - Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individualsAlan Winston
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
AIDS Res Hum Retroviruses 22:338-41. 2006..In this cohort of highly treatment-experienced individuals treated with NNRTI regimens, we did not observe a significant association between NNRTI plasma concentration and virological response... - Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunctionPatrick W G Mallon
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
J Infect Dis 198:1794-803. 2008..Rosiglitazone (RSG), a PPARgamma agonist, improves congenital lipoatrophy but not HIV lipoatrophy... - Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapyA Calmy
St Vincent s Hospital, Sydney, Australia
HIV Med 9:101-10. 2008..We investigated whether metabolic and body composition parameters could predict the development of LD over 2 years in adults initiating antiretroviral therapy (ART)... - No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trialAndrew Carr
St Vincent s Hospital, Sydney, Australia
Lancet 363:429-38. 2004..We postulated that rosiglitazone would improve HIV lipoatrophy... - Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infectionHandan Wand
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
AIDS 21:2445-53. 2007..Metabolic syndrome (MS) identifies individuals at risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Little is known about MS and its consequences following initiation of antiretroviral therapy (ART)... - HIV lipodystrophy: prevalence, severity and correlates of risk in AustraliaJ Miller
The National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
HIV Med 4:293-301. 2003..To establish the prevalence, severity and factors associated with the HIV lipodystrophy syndrome... - High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)John J Zaunders
Centre for Immunology, St Vincent s Hospital, Sydney, New South Wales, Australia
J Immunol 183:2827-36. 2009..In addition to revealing the true extent of Ag-specific human CD4(+) memory T lymphocytes, its greatest use will be as a simple in vitro monitor of CD4(+) T cell responses to Ags such as tuberculosis infection or vaccines... - A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophyDianne L Carey
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
J Acquir Immune Defic Syndr 46:581-9. 2007..Facial lipoatrophy can stigmatize and can reduce quality of life, self esteem, and antiretroviral adherence. Poly-L-lactic acid (PLA) injections seem safe and effective, but no randomized study has included objective endpoints... - Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trialAllison Martin
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
AIDS 24:2657-63. 2010..7, P = 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored... - Antivirals in the management of an influenza pandemicMary Ellen Harrod
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
Med J Aust 185:S58-61. 2006..The safety and efficacy (including resistance) of neuraminidase inhibitors against pandemic influenza or the virus of current concern in pandemic planning, influenza A/H5N1, is not known, and further research is needed... - Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair studyRebekah L Puls
National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, 45 Beach St, Coogee, New South Wales, Australia, 2034
Clin Infect Dis 51:855-64. 2010..Antiretroviral therapy is complicated by drug interactions and contraindications. Novel regimens are needed... 
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patientsAmit C Achhra
National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Cliffbrook Campus, Coogee, Sydney, New South Wales, Australia
AIDS 24:1877-86. 2010..To investigate the relative predictive value of CD4(+) metrics for serious clinical endpoints...- Restorative interventions for HIV facial lipoatrophyDianne Carey
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
AIDS Rev 10:116-24. 2008..However, well-designed studies with objectively assessed endpoints are needed to elucidate optimal treatments for this distressing condition... - Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trialsDianne Carey
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney 2052, New South Wales, Australia
J Antimicrob Chemother 65:1878-88. 2010..To compare lipid profiles in HIV-infected adults receiving atazanavir-based regimens... - Role of interleukin-2 in patients with HIV infectionSarah L Pett
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
Drugs 70:1115-30. 2010..Moreover, there was an excess of grade 4 clinical events in ESPRIT rIL-2 recipients. The results of the phase III clinical endpoint studies showed that rIL-2 has no place as a therapeutic agent in the treatment of HIV infection... - Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppressionHelen Byakwaga
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
AIDS Res Hum Retroviruses 25:756-76. 2009..Our results point to an advantage to commencing ART at higher CD4+ T cell strata. These data should be considered when estimating the optimal time to initiate ART... - A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infectionSarah L Pett
HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
AIDS Res Hum Retroviruses 26:653-61. 2010..The persistence and clinical meaning of these immunological changes during long-term exposure to this class of anti-HIV drugs are unknown, but may have implications for immunosurveillance of inflammation... - A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patientsSarah L Pett
HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
Antivir Ther 14:111-5. 2009..SCH532706 is a novel small molecule chemokine receptor-5 (CCRS) antagonist with high in vitro potency (mean 90% inhibitory concentration [IC90] 0.15-7.0 nM) against diverse HIV type-1 (HIV-1) isolates... - Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseJohn M Murray
National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW 2052, Australia
AIDS 21:2315-21. 2007..To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs... - Therapeutic vaccination against HIV: current progress and future possibilitiesRebekah L Puls
National Centre in HIV Epidemiology and Clinical Research (NCHECR, University of New South Wales (UNSW, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
Clin Sci (Lond) 110:59-71. 2006.... - A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individualsSarah L Pett
HIV, Immunology and Infectious Diseases Clinical Services, St Vincent s Hospital, Sydney, and National Centre in HIV Epidemiology and Clinical Research, University of NSW, Darlinghurst, Sydney, Australia
HIV Clin Trials 5:91-8. 2004..To establish the pharmacokinetics and safety of single-dose polyclonal caprine anti-HIV antibodies ((PE)HRG214)in HIV-1-infected individuals... - In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNAPatrick W G Mallon
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
J Infect Dis 191:1686-96. 2005..The effects of this mitochondrial dysfunction on lipid metabolism, at a molecular level in vivo, have not been described... - Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)S L Pett
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
HIV Med 12:219-27. 2011..cART alone (control arm) in HIV-infected adults with CD4 counts ≥300cells/μL, offered the opportunity to explore associations between bacterial pneumonia and rIL-2, a cytokine that increases the risk of some bacterial infections... - Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern AfricaGail V Matthews
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
AIDS 25:1727-35. 2011..To examine HIV and hepatitis B virus (HBV)-related outcomes in HIV/HBV-coinfected participants in the PHIDISA II study by use of HBV-active vs. non-HBV-active antiretroviral therapy (ART)... - Selective exclusion of treatment arms in multi-arm randomized clinical trialsMatthew G Law
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
Stat Med 22:19-30. 2003..However, the duration of time taken to recruit the study would be reduced. The implications for the design, monitoring and analysis of such RCTs are discussed... - Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trialDianne Carey
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
AIDS 19:1325-7. 2005..Changes in facial fat assessed by ultrasonography did not correlate significantly with more established objective measures of lipoatrophy severity. The measurement of malar fat using ultrasonography is not recommended... - Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophyJason C Kovacic
Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
Antivir Ther 10:135-43. 2005..This study sought to investigate the effects of rosiglitazone on endothelial function and other markers of cardiovascular risk in patients with HIV-related lipoatrophy... - Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolismKatherine Samaras
Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW 2010, Australia
Curr HIV Res 7:454-61. 2009..Only interventional, prospective studies will determine whether any nutritional strategy can assist in ameliorating the metabolic complications associated with HIV lipodystrophy... - Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalKatherine Samaras
Diabetes and Obesity Programme, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia
Diabetes Care 30:113-9. 2007..The purpose of this study was to report the prevalence of metabolic syndrome in HIV-infected patients and compare insulin resistance and total body, limb, and visceral fat and adipokines in those with and without metabolic syndrome... - An objective case definition of lipodystrophy in HIV-infected adults: a case-control studyA Carr
HIV, Immunology, and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
Lancet 361:726-35. 2003..However, an objective, validated definition of the disorder does not exist. We aimed to develop an objective, sensitive, specific, and broadly applicable case definition of HIV lipodystrophy... - HIV disease progression in a patient cohort treated via a clinical research network in a resource limited settingChris Duncombe
HIV Netherlands Australia Thailand Research Collaboration, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
AIDS 19:169-78. 2005..DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: A cohort of 417 patients enrolled in a series of randomized ART trials, between 1996 and December 2002... - CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studiesRoberto C Arduino
The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Clin Infect Dis 39:115-22. 2004..To more precisely quantitate the effect on CD4 cell response of 3 different doses of scIL-2 that were administered twice daily for 5 days every 8 weeks, the results of these 3 trials were pooled in a meta-analysis... - The development of artificial neural networks to predict virological response to combination HIV therapyBrendan Larder
The HIV Resistance Response Database Initiative, London, UK
Antivir Ther 12:15-24. 2007..The choice of an alternative regimen may be guided by a drug-resistance test. However, interpretation of resistance from genotypic data poses a major challenge... - Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 studyMartyn French
Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, WA, Australia
HIV Clin Trials 3:177-85. 2002..To assess and compare the efficacy and safety of three triple combination antiretroviral therapies in HIV-1-infected treatment-naive patients... - Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitorsSunee Sirivichayakul
Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
AIDS 17:1889-96. 2003..Switching from d4T/ddI to ZDV/3TC may be associated with a higher incidence of four or more NAM. Thus, suboptimal and dual NRTI therapy is not recommended for global application... - Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatmentDavid A Cooper
J Infect Dis 197:775; author reply 775-6. 2008 - Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-upJens D Lundgren
Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
J Infect Dis 197:1145-55. 2008..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported... - Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort dataBart Winters
Virco BVBA, Mechelen, Belgium
J Acquir Immune Defic Syndr 48:26-34. 2008..Clinically relevant cutoffs are needed for the interpretation of HIV-1 phenotypic resistance estimates as predicted by "virtual" phenotype HIV resistance analysis... - Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individualsAlison Clegg
Department of Immunology, Westmead Hospital, New South Wales 2145, Australia
Clin Immunol 106:36-40. 2003..03). This study highlights the importance of interactions between IL-2 and CCR5; at the clinical level, it argues for assessment of chemokine receptor genotype in IL-2 and perhaps other immune-based therapy trials... - Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infectionChaiwat Ungsedhapand
HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
J Acquir Immune Defic Syndr 36:693-701. 2004..Triple-nucleoside therapy with ZDV, 3TC, and ddI or d4T, 3TC, and ABC in patients with HIV infection is more effective in inducing a sustained virologic response than the dual combinations of ZDV and 3TC or ddI and d4T... - Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testingChris Birch
Victorian Infectioud Diseases Reference Laboratory, North Melbourne, Australia
J Acquir Immune Defic Syndr 32:57-61. 2003..02), however. In general, our results suggest that patients should continue current therapy until test results are available. A few patients would be expected to gain ARV drug-associated resistance mutations during this time, however... - Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited settingSomsamorn Mangclaviraj
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Int J STD AIDS 19:529-32. 2008..In settings where access to affordable treatment is improving, this study reinforces the importance of regular Pap smear screening in HIV-positive women, particularly those with low nadir CD4 counts and lower incomes... - Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12C Jane Dale
Department of Microbiology and Immunology, University of Melbourne, Royal Parade, Vic. 3010, Australia
Vaccine 23:188-97. 2004..Non-sterilising protection from a non-pathogenic HIV-1 challenge was observed. This study provides evidence of a safe, optimised, strategy for the generation of T-cell mediated immunity to HIV-1... - A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1Anthony D Kelleher
AIDS 20:294-7. 2006..The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9... - Determination of the underlying cause of death in three multicenter international HIV clinical trialsAlan R Lifson
University of Minnesota, Minneapolis, Minnesota 55454 1015, USA
HIV Clin Trials 9:177-85. 2008..Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials...